How Do You Decide the ESOP Exercise Price?

Direct answer: the exercise price must be based on a proper fair market value (FMV) determination, typically through a registered valuer's report under Section 247 of the Companies Act 2013. You can set the exercise price at, above, or below FMV — but each choice has different tax and accounting consequences. Most companies set it at or near FMV to keep things clean.

Sounds straightforward. In practice, this is where we see some of the most expensive mistakes in ESOP administration. A wrong exercise price doesn't just create paperwork problems — it creates tax liabilities for employees, audit qualifications for the company, and occasionally disputes that end up in front of tax authorities. Let's get it right.

Why the exercise price matters so much

The exercise price is the fulcrum of the entire ESOP. It determines:

1. How much wealth the employee creates (FMV at exercise minus exercise price)
2. How much perquisite tax the employee pays (same calculation — it's the taxable benefit)
3. How the company accounts for the grant (the difference between FMV at grant and exercise price drives the Ind AS 102 expense)

Set it too high and the options are worthless — no employee will exercise if they can buy cheaper elsewhere. Set it too low without understanding the consequences and you trigger tax and accounting issues. Set it arbitrarily and you're inviting scrutiny.

[Visual Placement: A balance scale illustration. Left side: "Exercise price too high → options underwater → no incentive." Right side: "Exercise price too low → tax & accounting complications." Centre: "At FMV → clean, defensible, aligned." Minimalist line art.]

The FMV requirement: what the law actually says

For unlisted companies, the Companies Act doesn't prescribe a single FMV method for ESOP exercise pricing. But the Income-tax Act does care — deeply — because the perquisite calculation under Section 17(2)(vi) depends on FMV at exercise.

In practice, this means you need a defensible FMV. The gold standard is a registered valuer's report under Section 247 of the Companies Act 2013. A registered valuer is a professional registered with the Insolvency and Bankruptcy Board of India (IBBI), qualified to value securities.

For listed companies, SEBI's SBEB (Share Based Employee Benefits) Regulations provide more specific guidance, and the market price typically serves as the reference point.

Here's what we tell every client: get the valuation done by someone qualified, in writing, dated appropriately, using a recognised method (typically DCF, comparable company multiples, or net asset value — or a combination). This isn't bureaucratic box-ticking. It's your defence if the tax department ever asks "says who?"

The three pricing choices (and what each triggers)

Option 1: Exercise price = FMV (the clean route)

This is what most well-advised companies do. The employee pays fair value. There's no upfront perquisite at grant. Tax is triggered only at exercise, based on the appreciation since grant.

Accounting is straightforward. The Ind AS 102 expense is based on the option's fair value at grant date (calculated using Black-Scholes or a similar model), spread over the vesting period.

Option 2: Exercise price below FMV (the discount route)

Some companies offer options at a discount — say, FMV is ₹500 but the exercise price is ₹100. This is legal, but it has consequences.

The discount (₹400 per share in this example) may be treated as a perquisite at the time of grant in certain circumstances, not just at exercise. The accounting expense is higher because the option's fair value at grant is higher. And if the discount is seen as excessive or unjustified, it raises questions.

We see this most often at very early-stage startups where the founders want to be generous. The intention is good. But the execution needs care — document the rationale, get board approval, and make sure employees understand the tax implications.

Option 3: Exercise price above FMV (the premium route)

Rare, but it happens — usually when a company wants to set a stretch target. If the exercise price is above the current FMV, the options are "underwater" from day one. They only have value if the company grows beyond that price.

There's nothing wrong with this legally, but it's a tough sell to employees. "Here's your incentive — it's currently worthless, but it might be worth something someday" isn't the most motivating pitch.

[Visual Placement: A three-row table illustration comparing the options. Columns: "Pricing" | "Employee tax" | "Company accounting" | "Best for." Rows for At FMV / Below FMV / Above FMV. Clean, scannable, with colour-coded "complexity" indicators.]

Mistakes we see in the real world

Mistake #1: Using the last funding round valuation as FMV.

This is the most common shortcut, and it's often wrong. Your Series A valuation from eighteen months ago doesn't reflect today's FMV — especially if you've grown (or shrunk) since then. For tax purposes, the FMV must be as of the relevant date (grant date for scheme purposes, exercise date for perquisite calculation). An outdated number is not a defensible number.

Mistake #2: Getting one valuation and using it forever.

Valuations go stale. If you're granting options quarterly but your valuer's report is a year old, you have a problem. We recommend refreshing the valuation at least annually, and always before a major grant cycle. The cost of a valuation report (typically a modest professional fee) is trivial compared to the cost of defending an indefensible number.

Mistake #3: Letting the CFO pick a number.

We've seen companies where the exercise price was set based on "what feels right" or "what we did last time." This is not a valuation methodology. If the tax authorities ask for your basis and your answer is "the CFO thought ₹200 seemed reasonable," you're in trouble. Get the report. Every time.

Mistake #4: Ignoring the Ind AS 102 impact.

The accounting expense for ESOPs is real and hits your P&L. For a company with a large option pool, this can be material — we've seen it swing startups from "profitable" to "loss-making" on paper. Founders are sometimes surprised. Finance teams shouldn't be. Model the expense before you finalise the grant, not after.

Mistake #5: Different prices for different employees without documentation.

It's fine to have different exercise prices for different grant cycles (FMV changes over time, after all). It's a problem when two employees in the same cycle get different prices without a documented reason. Inconsistency without justification looks like favouritism at best and manipulation at worst. If there's a reason — different roles, different grant dates, performance-based — write it down.

A scenario from our files

A growth-stage company came to us after their statutory auditor flagged their ESOP accounting. They'd been granting options for three years using an exercise price set at incorporation — ₹10 per share. The company's FMV had grown to roughly ₹800. They'd never obtained a fresh valuation.

The problems cascaded: the Ind AS 102 expense was massively understated (three years of financials needed restatement), employees faced unexpected perquisite tax on the huge spread, and the auditor wouldn't sign off until it was fixed. The remediation took four months and cost significantly more than three annual valuation reports would have.

The lesson isn't complicated: FMV is not a one-time exercise. It's an ongoing discipline.

What good looks like

Here's the process we recommend to every client:

1. Engage a registered valuer before each major grant cycle (at least annually)
2. Document the valuation method — DCF, comparables, NAV, or a weighted combination
3. Set the exercise price based on the valuer's FMV (at FMV for simplicity, or document the rationale for any discount/premium)
4. Get board approval for both the valuation and the exercise price
5. Communicate clearly to employees — what the price is, how it was determined, and what it means for their tax
6. Refresh regularly — don't let the valuation go stale

[Visual Placement: A six-step vertical process diagram, numbered 1–6, each step as a rounded rectangle connected by arrows. Title: "The FMV Discipline: Getting Exercise Pricing Right." Professional, clean, suitable for a slide deck.]

Your next step

Pull out your last ESOP grant documentation. Check three things: When was the FMV determined? Who determined it? Is the report still current? If you can't answer all three confidently, that's your starting point. Engage a registered valuer before your next grant — not after.

Frequently asked questions

Who can determine FMV for ESOP purposes in a private company? A registered valuer under Section 247 of the Companies Act 2013, registered with IBBI. While the Companies Act doesn't mandate a specific method for ESOP pricing, using a registered valuer provides the most defensible FMV for both corporate law and income-tax purposes.

Can the ESOP exercise price be lower than FMV? Yes, it's legally permitted. However, the discount has tax implications (potential perquisite at grant) and increases the accounting expense under Ind AS 102. The rationale for any discount should be documented and board-approved.

How often should we refresh our company valuation for ESOPs? At minimum, annually — and always before a significant new grant cycle. If there are material changes (new funding round, major revenue shift, market disruption), refresh sooner. An outdated valuation is a common audit and tax issue.

What valuation methods are typically used for unlisted company ESOPs? The most common are Discounted Cash Flow (DCF), Comparable Company Multiples (CCM), and Net Asset Value (NAV). Registered valuers often use a weighted combination. The method should be appropriate for the company's stage — DCF for growth companies with projections, comparables for companies with listed peers, NAV as a floor.